Bain Capital
Bain Capital is a Boston-based multi-asset alternative investment firm that sources, funds, and manages investments across private equity, venture capital, credit, and public equity. Founded in 1984, it operates globally with specialized units focused on growth and buyout investments, life sciences, and impact-oriented opportunities. The firm backs companies across sectors including healthcare and life sciences, technology, software and data services, financial services, consumer, manufacturing, and industrials, spanning from early-stage ventures to growth equity and large-scale acquisitions. It emphasizes value creation through strategic support and partnerships, leveraging deep operating experience and a global network. Its life sciences arm targets pharmaceutical, biotechnology, medical device, and diagnostic companies; the Double Impact unit pursues market-rate returns alongside measurable social and environmental benefits; Bain Capital Ventures backs technology-enabled businesses from seed to growth across enterprise software, infrastructure, and services. The firm maintains offices in Boston and major markets worldwide, aiming to deliver competitive returns while supporting innovation and economic development.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Jennifer Davis
Partner, Private Equity, Consumer and Retail Vertical and Member of the North American Private Equity Team
Liraz Evenor
Managing Director Private Equity and Director in the Consumer and Retail Vertical & Member of the Portfolio Group for North America Private Equity
Alison Holmes
Principal, Private Equity and Consumer, Retail and Dining Vertical & Member of the North American Private Equity Team
Andrew Kaplan
Partner, Private Equity and Healthcare Vertical and Member Of The North American Private Equity Team
Christopher Kastner
Managing Director, Portfolio Group and Member of the North American Private Equity team
Phillip Loughlin
Partner, Global Head of the Financial and Business Services Vertical and Member of the Consumer / Retail Vertical
James Mackey
Principal, Private Equity and Technology Vertical and Member of the North American Private Equity Team
Giacomo Massetti
Managing Director, Consumer and Industrial Verticals and Member of the European Private Equity team
Cara Nealon
Senior Vice President, Portfolio Group and Member of the North American Private Equity Team
Radhika Subramanian
Principal, Consumer, Retail and Financial services and a Member of the Asia Pacific Private Equity team
Past deals in Medical Devices
HeartFlow
Convertible Note in 2025
HeartFlow specializes in precision heart care, offering a non-invasive solution for diagnosing coronary artery disease. Its proprietary HeartFlow FFRCT Analysis uses artificial intelligence to create a personalized 3D model of the heart, enabling clinicians to evaluate blood flow and determine optimal treatment. Commercially available in the United States, UK, Canada, Europe, and Japan.
Solid Biosciences
Post in 2025
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Somacis
Acquisition in 2024
Somacis SpA specializes in the manufacturing and supply of printed circuit boards (PCBs), including rigid, flex, and rigid-flex types. The company is recognized for its expertise in high-density interconnect (HDI) and flex-rigid PCBs, offering solutions that accommodate up to 50 layers. Somacis provides a range of products such as buried components, metal core solutions, RF/microwave products, graphic overlays, touch screens, and custom membrane switches. Founded in 1972 and headquartered in Castelfidardo, Italy, Somacis operates additional production facilities in Manfredonia, Italy; Poway, California; and Guangdong, China. The company serves various industries, including telecommunications, aerospace, defense, industrial, medical, automotive, and information technology, catering to both time-sensitive and mass production needs.
Imperative Care
Series E in 2024
Founded in 2015, Imperative Care specializes in developing innovative medical technologies aimed at improving stroke treatment. Its flagship products include the Large Distal Platform catheter for deeper reach and the ZOOM Aspiration System for clot removal. The company's mission is to enhance treatment speed and effectiveness, ultimately optimizing patient recovery.
Kestra Medical Technologies
Private Equity Round in 2024
Kestra Medical Technologies develops and commercializes wearable medical devices and digital health solutions for cardiovascular care. The company provides monitoring, data collection, and therapeutic intervention to protect at-risk patients, with real-time and retrospective analysis. Its Cardiac Recovery System platform integrates monitoring, therapy, digital health tools, and patient support into a single solution, anchored by the ASSURE wearable cardioverter defibrillator designed to prevent sudden cardiac death and aid cardiac recovery. Kestra aims to transform patient outcomes in cardiovascular disease through intuitive, connected technologies.
CereVasc
Series B in 2024
CereVasc, Inc. is a medical device company based in Auburndale, Massachusetts, specializing in the development of innovative, minimally invasive treatments for neurological diseases. The company has created the eShunt System, an endovascularly deliverable cerebrospinal fluid (CSF) shunt designed to replace traditional surgical methods for treating communicating hydrocephalus. This system aims to eliminate the need for invasive surgery, general anesthesia, and hospitalization, which are typically associated with the conventional use of ventriculo-peritoneal shunts. By providing a less invasive alternative, CereVasc seeks to improve patient outcomes and reduce the overall costs related to the surgical management of life-threatening neurological conditions. Established in 2014, CereVasc is focused on advancing healthcare solutions that enhance the treatment of various neurological brain disorders.
Century Therapeutics
Post in 2024
Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.
Solid Biosciences
Post in 2024
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Gynesonics
Venture Round in 2023
Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.
HeartFlow
Series F in 2023
HeartFlow specializes in precision heart care, offering a non-invasive solution for diagnosing coronary artery disease. Its proprietary HeartFlow FFRCT Analysis uses artificial intelligence to create a personalized 3D model of the heart, enabling clinicians to evaluate blood flow and determine optimal treatment. Commercially available in the United States, UK, Canada, Europe, and Japan.
Solid Biosciences
Post in 2022
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
JenaValve Technology
Series C in 2022
JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogyâ„¢ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.
Legacy
Series B in 2022
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
Classys
Acquisition in 2022
Classys specializes in manufacturing medical equipment.
Hyperfine
Post in 2021
Hyperfine is a pioneering medical device company that developed Swoop®, the world's first FDA-cleared point-of-care MRI system. Designed to enhance patient access to critical care, Swoop produces high-quality images rapidly and at a lower cost than conventional MRIs, enabling clinicians to diagnose and treat patients swiftly in various clinical settings.
Imperative Care
Series D in 2021
Founded in 2015, Imperative Care specializes in developing innovative medical technologies aimed at improving stroke treatment. Its flagship products include the Large Distal Platform catheter for deeper reach and the ZOOM Aspiration System for clot removal. The company's mission is to enhance treatment speed and effectiveness, ultimately optimizing patient recovery.
ViaCyte
Series D in 2021
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.
Solid Biosciences
Post in 2020
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Rapid Micro Biosystems
Venture Round in 2020
Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.
Affinivax
Series B in 2020
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.
ViaCyte
Venture Round in 2020
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.
Verana Health
Series D in 2020
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQâ„¢, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.
JenaValve Technology
Series D in 2020
JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogyâ„¢ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.
Legacy
Seed Round in 2020
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
Kestra Medical Technologies
Private Equity Round in 2020
Kestra Medical Technologies develops and commercializes wearable medical devices and digital health solutions for cardiovascular care. The company provides monitoring, data collection, and therapeutic intervention to protect at-risk patients, with real-time and retrospective analysis. Its Cardiac Recovery System platform integrates monitoring, therapy, digital health tools, and patient support into a single solution, anchored by the ASSURE wearable cardioverter defibrillator designed to prevent sudden cardiac death and aid cardiac recovery. Kestra aims to transform patient outcomes in cardiovascular disease through intuitive, connected technologies.
Imperative Care
Series C in 2019
Founded in 2015, Imperative Care specializes in developing innovative medical technologies aimed at improving stroke treatment. Its flagship products include the Large Distal Platform catheter for deeper reach and the ZOOM Aspiration System for clot removal. The company's mission is to enhance treatment speed and effectiveness, ultimately optimizing patient recovery.
Arcutis Biotherapeutics
Series C in 2019
Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.
IQVIA
Post in 2019
IQVIA is a global leader in advanced analytics, technology solutions, and contract research services for the life sciences industry. It specializes in generating and analyzing large-scale health information to identify disease patterns and optimize treatment paths.
Solid Biosciences
Post in 2019
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Kantar
Acquisition in 2019
Kantar, a division of WPP, is a global leader in data-driven insights and consulting. With a team of 26,500 employees across 95 countries, Kantar unites diverse expertise in market research, analytics, and consulting to provide clients with comprehensive business insights. Its services span the entire consumer cycle, aiding clients in strategic decision-making. Kantar Health, a division of Kantar, specializes in data, analytics, and research for the life sciences industry, helping clients bring safe and effective treatments to patients worldwide.
Legacy
Seed Round in 2019
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
ViaCyte
Series D in 2018
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.
Arcutis Biotherapeutics
Series B in 2018
Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.
Rapid Micro Biosystems
Venture Round in 2018
Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.
Gynesonics
Private Equity Round in 2018
Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.
Halo Health
Series A in 2017
Halo Health Inc. is a technology company that specializes in providing clinical communication and care coordination solutions for healthcare organizations in the United States. The company offers a comprehensive clinical communication platform that includes various tools such as secure messaging for healthcare professionals, an enterprise-wide scheduling system, and patient engagement features. Its offerings, which include Halo Messaging, Halo Pronto, Patient Halo, Halo Handoff, Halo Link, and Halo Patient Coordinator, aim to enhance real-time communication among physicians, nurses, and staff, thereby streamlining patient care. The platform integrates seamlessly with hospital systems, allowing users to access electronic health records, manage on-call schedules, and coordinate care effectively. Halo Health's solutions are designed to improve response times, reduce readmission rates, and facilitate efficient transitions of care. Founded in 2010 and headquartered in Cincinnati, Ohio, Halo Health was previously known as Doc Halo, LLC until it rebranded in May 2018.
Hugel Control
Post in 2017
Hugel, Inc. is a biopharmaceutical company based in Chuncheon-si, South Korea, specializing in the development and manufacturing of innovative medical products. The company offers a range of Botulinum Toxin products under various brand names, including Botulax and Hugel Toxin, for medical applications such as treating eyelid convulsions, severe wrinkles, upper limb stroke, and specific foot deformities in children. Additionally, Hugel produces hyaluronic acid fillers marketed under brands like Dermalax and Revigance, as well as cosmetics under the Wellage brand. The company is committed to enhancing global health and quality of life through advanced technology and creativity, operating manufacturing facilities in Shinbuk and Geodu. Founded in 2001, Hugel aims to expand its international presence in the biopharmaceutical sector.
Solid Biosciences
Series C in 2017
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Asia Pacific Medical Group
Acquisition in 2016
Asia Pacific Medical Group operates a network of hospitals designed to cater to both local and international patients across Southeast Asia. The organization provides a comprehensive range of medical services, including neurology, oncology, cardiovascular medicine, pediatrics, and dermatology. Their facilities are equipped to deliver advanced treatments such as gamma knife therapy, neurosurgery, and plastic surgery, among others. By focusing on affordability, Asia Pacific Medical Group aims to make high-quality healthcare accessible, allowing patients to receive effective treatment for various medical conditions in a supportive environment.
Remedy Partners
Series B in 2015
Remedy Partners, Inc. is a health technology company that specializes in developing software solutions and services aimed at organizing and financing healthcare delivery around patient episodes of care. The company provides analytics, technology, and provider networks to facilitate bundled payment programs for various stakeholders, including payers, employers, and at-risk healthcare providers. Its offerings include contracting programs for payers, administrative support for bundled payment contracts, and concierge-level services for patients, enhancing their connection with care teams. Remedy Partners serves a diverse clientele, including government agencies, managed care organizations, self-funded employers, healthcare systems, and physician groups. Founded in 2011 and headquartered in Darien, Connecticut, with additional offices in New York and Shelton, the company delivers its services to healthcare partners nationwide. In 2019, Remedy Partners was acquired by Signify Health, LLC.
National Cardiovascular Partners
Venture Round in 2014
National Cardiovascular Partners is an operator of outpatient endovascular, vascular, and cardiovascular services, focusing on providing care in a convenient setting. Partnering with over 200 physicians, the company manages 21 outpatient vascular centers across six states. Its facilities include independent cardiac catheterization and vascular labs, where physician entrepreneurs serve as majority stakeholders, retaining both clinical and financial control. National Cardiovascular Partners oversees the administrative aspects of these centers, allowing physician partners to concentrate on delivering high-quality and innovative patient care.
Bio Products Laboratory Holding
Acquisition in 2013
Bio Products Laboratory Holding manufactures and supplies blood plasma products. It transforms blood plasma into treatments for immune deficiencies, neurological diseases, and hemophilia.
Physio-Control
Acquisition in 2011
Physio-Control, Inc. specializes in emergency medical response products and services, with a strong reputation for its LIFEPAK defibrillators, which are widely recognized by first responders and healthcare professionals. The company focuses on developing advanced technologies and designing high-quality devices that meet the needs of both clinical care providers and everyday citizens. In addition to defibrillators, Physio-Control offers chest compression systems and cloud-based data management solutions, establishing itself as a leader in the industry. Its commitment to customer-driven product development has set a benchmark for quality and reliability in emergency medical equipment.
Boston Heart Diagnostics
Series C in 2010
Boston Heart Diagnostics is a healthcare company based in Framingham, Massachusetts, specializing in cardiovascular disease management. The company offers a comprehensive range of laboratory techniques, including gas chromatography, gel electrophoresis, genetic testing, and liquid chromatography. Its proprietary lipid testing technology enables ongoing monitoring of patients' conditions and facilitates the precise selection of effective pharmaceutical treatments for dyslipidemia. Unlike traditional lipid testing methods that focus primarily on initial screenings and may take up to six months to assess treatment efficacy, Boston Heart's approach allows for evaluations within the first six weeks. By combining advanced therapy guidelines and patient support services, Boston Heart Diagnostics aims to provide personalized treatment options that enhance patient health and improve disease management outcomes.
Physio-Control
Acquisition in 1994
Physio-Control, Inc. specializes in emergency medical response products and services, with a strong reputation for its LIFEPAK defibrillators, which are widely recognized by first responders and healthcare professionals. The company focuses on developing advanced technologies and designing high-quality devices that meet the needs of both clinical care providers and everyday citizens. In addition to defibrillators, Physio-Control offers chest compression systems and cloud-based data management solutions, establishing itself as a leader in the industry. Its commitment to customer-driven product development has set a benchmark for quality and reliability in emergency medical equipment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.